Targeting B Cells and Plasma Cells in Glomerular Disease.
Syeda Behjat Ahmad, J Ashley Jefferson
https://pubmed.ncbi.nlm.nih.gov/40465397/Actively Recruiting
Led by Novartis Pharmaceuticals · Updated on 2026-10-13
348
Participants Needed
51
Research Sites
N/A
Total Duration
This research aims to evaluate the long-term efficacy and safety of ianalumab treatment in adults with lupus nephritis who have completed the SIRIUS-LN core study. The study focuses on two groups patients who achieved complete or partial renal response and stopped study treatment, and those who continue or start open-label ianalumab because they did not meet response criteria or were already receiving it. This open-label extension can last up to six years. Participants are divided into two cohorts. Cohort 1 includes patients who responded to previous treatment and will withdraw from the study drug while continuing standard care, with the option to restart ianalumab if they experience renal flare. Cohort 2 includes patients who did not respond or were already on open-label ianalumab and will continue receiving this treatment during the extension. The study allows investigators to decide if continuing in the extension is beneficial for each participant. Throughout the study, participants will be monitored for kidney flare-ups, changes in immunosuppressive medication, adverse events, and the presence of antibodies against ianalumab. Assessments include safety and efficacy measures over up to six years, with the primary outcomes focusing on time to renal flare or adverse events depending on the cohort. Participants will have regular evaluations to track their health status and treatment effects during this period.
CONDITIONS
Phase III Extension Study of Efficacy and Safety of Ianalumab With or Without Study Treatment Withdrawal in Participants With Lupus Nephritis (SIRIUS-LN Extension)
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Novartis Pharmaceuticals
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Ianalumab continuation | Treatment withdrawal (no intervention) | Typical lupus nephritis maintenance therapy |
|---|---|---|---|
| What it is | Continuation of investigational antibody Ianalumab beyond Week 144 in participants from the core study | Withdrawal arm where study treatment is stopped and no further intervention is given | Typical maintenance therapy in lupus nephritis involves immunosuppressive agents such as mycophenolate plus steroids, sometimes with addition of belimumab |
| Role in trial | Investigational continuation regimen | Comparator arm with no further study treatment | Contextual reference therapy not part of this trial |
| Primary use | Evaluate safety, immunogenicity, and time to renal flare while continuing Ianalumab | Observe outcomes such as renal flare or immunosuppression need without Ianalumab | Maintain disease control with established immunosuppressive maintenance regimens |
| How it is given or performed | Participants continue to receive Ianalumab as per extension protocol | No study drug is given after Week 144 | Regimens typically involve oral immunosuppressants and tapering steroids, sometimes with biologic infusion or injection |
| Evidence status | Safety and flare‑delay outcomes are under active investigation in this extension study | Outcomes without Ianalumab continuation are captured in trial comparison | Guidelines show benefit of combination maintenance regimens for preventing flares and preserving kidney function |
| Important risks | Extension phase will record adverse events and serious adverse events, including immunogenicity | Risks include potential disease flare or need for additional immunosuppression | Known risks include infection, steroid toxicity, and immunosuppressive side effects |
| Important limitations | Extension participants already tolerated Ianalumab through Week 144, limiting generalizability | Comparator is not blinded and reflects withdrawal rather than standard discontinuation practice | Standard‑of‑care comparator is contextual only and not directly compared in trial |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 6 years
Participants either stop study treatment and continue standard care or receive open-label ianalumab depending on their previous response. Those who stop treatment may restart ianalumab if kidney flare occurs.
Regular visits for monitoring and safety assessments
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Syeda Behjat Ahmad, J Ashley Jefferson
https://pubmed.ncbi.nlm.nih.gov/40465397/Novartis Pharmaceuticals
Lead Sponsor